The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Sarepta’s first ever controlled study, of a Duchenne muscular dystrophy gene therapy, brings the markets down to earth.
The group’s latest data cut with XMT-1536 in ovarian cancer raises several red flags.
Aurinia’s only project is due in front of the FDA, and outcomes are expected for Merck KGaA, Bayer and Merck & Co.
As Curis clinically backs a novel oncology mechanism, several companies might review their own similarly acting projects.
Usually a double pivotal trial hit would be cause for celebration, but it might not be enough for Roche.
The whole haemophilia gene therapy field will be hoping that a case of liver cancer in etranacogene dezaparvovec’s pivotal trial is not treatment related.